Format

Send to

Choose Destination
Nat Commun. 2018 Apr 18;9(1):1538. doi: 10.1038/s41467-018-04004-2.

Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.

Author information

1
Division of Translational Cell Genetics, Medical University of Innsbruck, 6020, Innsbruck, Austria.
2
Pathology of the University Hospital Schleswig-Holstein, Campus Luebeck and Research Center Borstel, Leibniz Lung Center, 23538, Leubeck, Germany.
3
Biocenter, Division of Bioinformatics, Medical University of Innsbruck, 6030, Innsbruck, Austria.
4
Tumor Immunology, Tyrolean Cancer Institute & Internal Medicine V, 6020, Innsbruck, Austria.
5
Department of Pathology, University of Basel, University Hospital Basel, 4031, Basel, Switzerland.
6
Medical Clinic III, Oncology, Hematology & Rheumatology, University Clinic Bonn, 53127, Bonn, Germany.
7
Division of Translational Cell Genetics, Medical University of Innsbruck, 6020, Innsbruck, Austria. gottfried.baier@i-med.ac.at.

Abstract

Analyzing mouse tumor models in vivo, human T cells ex vivo, and human lung cancer samples, we provide direct evidence that NR2F6 acts as an immune checkpoint. Genetic ablation of Nr2f6, particularly in combination with established cancer immune checkpoint blockade, efficiently delays tumor progression and improves survival in experimental mouse models. The target genes deregulated in intratumoral T lymphocytes upon genetic ablation of Nr2f6 alone or together with PD-L1 blockade reveal multiple advantageous transcriptional alterations. Acute Nr2f6 silencing in both mouse and human T cells induces hyper-responsiveness that establishes a non-redundant T-cell-inhibitory function of NR2F6. NR2F6 protein expression in T-cell-infiltrating human NSCLC is upregulated in 54% of the cases (n = 303) and significantly correlates with PD-1 and CTLA-4 expression. Our data define NR2F6 as an intracellular immune checkpoint that suppresses adaptive anti-cancer immune responses and set the stage for clinical validation of targeting NR2F6 for next-generation immuno-oncological regimens.

PMID:
29670099
PMCID:
PMC5906604
DOI:
10.1038/s41467-018-04004-2
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center